Implanet SA (DE:IM11)

FRANKFURT:IM11

IM11

Implanet SA

RESEARCH TOOLSreports

Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.08 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€26.55M

Enterprise Value€29.46M

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.24

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthStrong multi-year revenue growth demonstrates accelerating market penetration and product adoption in core orthopedic and spine segments. That top-line momentum creates a durable base for scaling fixed-cost absorption and generating operating leverage if the trend continues over the next several quarters.

Improving Gross MarginA marked rise in gross margin reflects better unit economics, pricing or product mix. Higher gross margins increase per-sale contribution to covering fixed costs, improving structural profitability potential and reducing cash burn sensitivity as sales scale over months to years.

Recurring, Procedure-Linked RevenueThe business sells implant platforms and consumables that generate repeat purchases tied to surgical procedures. This platform-driven, recurring demand pattern supports higher customer lifetime value, stronger visibility into mid-term revenue and stickiness with hospital and surgeon customers.

Bears Say

Negative Cash GenerationPersistent negative operating and free cash flow means the company continues to burn cash despite improvements. That reliance on external funding constrains runway and strategic flexibility, increasing the risk that growth initiatives or commercialization plans will be delayed or require dilutive financing.

High Leverage / Thin EquityA very elevated debt load relative to minimal equity sharply reduces financial resilience. High leverage raises refinancing and interest risk, limits ability to absorb operational shocks, and makes the company dependent on capital markets or lenders to fund growth until profitability is achieved.

Material Ongoing LossesDespite revenue and margin gains, sustained net losses undermine self-funding and constrain reinvestment options. Ongoing unprofitability increases the probability of further capital raises, which can dilute shareholders and complicate long-term planning if improvements stall.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.08 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €26.55M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 106 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its subsidiaries, researches and develops, manufactures, and sells spinal and orthopedic implants. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation. The company also provides knee prostheses under the Madison name. Implanet S.A. has a strategic partnership with Shanghai Sanyou Medical Co, Ltd. The company was founded in 2006 and is based in Martillac, France.